-- 独立系調査会社CFRAは、に対し、以下の調査レポートを提供しました。CFRAのアナリストは、以下のように見解をまとめています。12ヶ月目標株価を1ドル引き上げ、87ドルとします。これは、今後12ヶ月のEPS予想の22.0倍に相当し、同業他社およびCMSの過去3年間の平均18.4倍を上回ります。2026年と2027年のEPS予想はそれぞれ0.02ドル引き下げ、3.88ドルと4.17ドルとします。CMSは、第1四半期の調整後EPS成長率が10.8%だったと発表しました。CMSは、2つのハイパースケーラーデータセンターが契約条件について商業契約を締結し、第1四半期だけで110MWの新規負荷契約を締結したと発表しました(これは2025年の契約総量を上回る)。これらの負荷は2028年から順次稼働開始予定で、すべて既存計画に追加されるものです。新規負荷1GWごとに20億~50億ドルの設備投資機会が生まれ、同時に顧客料金の平均上昇率を約2%抑制できます。当社は、CMSが短期的に競争力のあるEPS(2025~2028年の年平均成長率約7.6%)と配当成長率(約5.8%)の軌道を描いていると考えています。ミシガン州は、国内でも最も支援的な規制当局の一つであり、CMSの直近の電気料金改定結果は、複数の回復メカニズムを通じて慎重な投資を支援する規制当局の意欲を明確に示しています。
Related Articles
Research Alert: CFRA Lowers View On Bio-rad Laboratories To Sell From Hold
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target by $45 to $235, reflecting a 25.6x multiple of our 2026 EPS estimate (down to $9.17 from $10.15; we cut our 2027 EPS estimate to $9.97 from $10.68), a discount to BIO's three-year historical forward average of 29.5x. Rather than a dramatic cut to National Institutes of Health (NIH) funding, Congress approved a modest increase for 2026 funding, helping reduce research budget concerns that loomed during 2025. However, BIO and peers anticipate that research spending growth from academic and early-stage biotech could remain muted over the near term as academic institutions adjust. The outlook for 2026 anticipates ongoing pressure, with BIO cutting sales and margin expectations during the Q1 earnings report, citing headwinds arising from the U.S.-Iran conflict in the Middle East such as weaker diagnostics sales and higher freight and fuel costs.
Comfort Systems USA Insider Sold Shares Worth $889,890, According to a Recent SEC Filing
Pablo G. Mercado, Director, on April 30, 2026, sold 500 shares in Comfort Systems USA (FIX) for $889,890. Following the Form 4 filing with the SEC, Mercado has control over a total of 3,000 common shares of the company, with 3,000 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1035983/000153524626000004/xslF345X05/form4-05012026_040501.xml
Kaiser Aluminum Insider Sold Shares Worth $524,757, According to a Recent SEC Filing
Keith Harvey, Director, President & CEO, on April 29, 2026, sold 3,031 shares in Kaiser Aluminum (KALU) for $524,757. Following the Form 4 filing with the SEC, Harvey has control over a total of 94,308 common shares of the company, with 94,308 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/811596/000119312526201545/xslF345X05/ownership.xml